 T.cruzi infection is endemic in the Bolivian Chaco  Childhood T.cruzi seroprevalence was 0.22, rising steeply with age  Persistent transmission persists shown by FOI annual incidence estimate of 0.021  School-based screening with rapid tests is a practical approach in remote areas  Current intermittent vector control practises in the Bolivian Chaco are suboptimal
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Chagas Disease in the Bolivian
The semi-arid lowland of the Gran Chaco spanning parts of Bolivia, Paraguay and Argentina is reported to have the highest prevalence of T.cruzi infection in the world, due to well documented local challenges in triatomine vector control and surveillance (Gurtler, 2009 , World Health Organisation, 2015 Chronic infection with T. cruzi, the aetiological agent of Chagas disease, leads to clinically significant cardiovascular and gastrointestinal disease in an estimated 30-40% of cases, and treatment remains challenging (Perez-Molina and Molina, 2018) . Untreated, infection persists lifelong, and thus prevalence increases with age, reflecting cumulative incidence.
Children are often tested as a sentinel population for recent transmission, with effective vector control rapidly decreasing seroprevalence in this subpopulation. Despite this, published childhood seroprevalence data from the Bolivian Chaco are limited; to date, few seroscreening studies have been published, with the most recent reporting a seroprevalence of 19.8% (Samuels et al., 2013) . Here, we report the results of a recent screening study, demonstrating persistent high levels of infection indicating sustained vector transmission.
Methods

Screening
At the request of the local authorities, we screened school-age children in July to August 2017 in a village near Camiri, the capital of Cordillera province in the Bolivian Chaco. All children attending the local primary and secondary schools were eligible to participate, with no age restriction. The child's parent or guardian provided written informed consent, and verbal assent Seropositive individuals were offered benznidazole treatment in accordance with local governmental protocols. The houses of infected children were sprayed by the local control program before commencement of treatment.
Analysis
Descriptive statistics were generated using IBM SPSS v24. The force of infection (FOI) was calculated using a catalytic model applied to age-prevalence data (Courtenay et al., 1994) . The mean age of seropositive individuals was 13 (SD 3.9, range 5-21); 47.3% were male. As expected, prevalence increased steeply with age.
The age-prevalence increased with age with no apparent recovery, as shown in Figure 1 . The annual incidence estimated from the FOI was 0.021 (95% CI=0.0128-0.0294).
The observed seroprevalence is similar to that previously described by Samuels et al in 2013 (age < 16 = 18.9% and 19 .8% respectively) in a nearby municipality. This, coupled with the high FOI estimate, demonstrates significant recent vector transmission. Although the ChagasDetectPlus specificity (91.9%) in this study was lower than in previous analyses, screening in this rural village was greatly facilitated by the use of this rapid test (Eguez et al., 2017 , Shah et al., 2014 .
Pairing a highly sensitive rapid test with a more specific confirmatory test allows efficient screening, even in a challenging community setting. Practicality was further enhanced by our school-based screening model, which provided an accurate record of potential participants without reliance on census data, and facilitated timely testing.
Poor treatment compliance with the 60-day treatment course and frequent adverse drug reactions have made screen-and-treat programmes hard to justify in a healthcare system with limited resources. Recent results from the BENDITA Phase II trial (Drugs for Neglected Diseases
Initiative, 2019) suggest that shorter courses of benznidazole may provide equivalent parasitological efficacy to the current 60-day standard course. If Phase III trials confirm these results, large scale paediatric screen-and-treat programmes may become feasible in resource poor settings. We advocate school-based screening with rapid tests as a practical way to achieve this, at least in areas such as the study community where school attendance is high. In communities where a significant proportion of children do not attend school, school-based designs may miss high risk children.
Our results add weight to the current consensus that significant vector transmission persists, and that the current intermittent vector control practises in the Bolivian Chaco are suboptimal, but critical to improve.
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